Living with a chronic illness changes how you see the world. Time is no longer measured in milestones or seasons, but in flares and remissions, blood tests and hospital appointments. Chronic illnesses like Crohn's Disease are not short sprints; they are marathons. Unlike certain forms of cancer, where treatment may lead to a cure, Crohn's has no cure. It is lifelong, unpredictable, and relentless. You do not "beat" it. You learn to live alongside it and to manage.
That reality shapes how you understand medicine. Treatment is not something you take for a while and then leave behind. It becomes part of your routine, part of your planning, part of how you imagine your future. For people like me, discussions about medicine - especially generic medicines and biosimilars - are not abstract policy debates or budgetary exercises. They are about whether we can live stable, productive lives over the long term.
Biologic medicines transformed the treatment of Crohn's Disease. They brought control where there had been chaos, and quality of life where there had been pain and constant uncertainty. But they also came with an unavoidable truth: these treatments are expensive, and for a condition with no cure, they may be needed indefinitely. That reality makes the conversation around sustainability, access, and responsibility unavoidable.
Generic medicines are often misunderstood. At their simplest, generics are medicines that are the same as branded drugs whose patents have expired. They contain the same active ingredient, work in the same way, and are subject to the same safety and quality standards. The main difference is cost, because the manufacturer did not have to repeat the original research process. Generics have supported healthcare systems safely and effectively for decades.
Biologics, however, are more complex. They are produced using living cells, which means they cannot be copied exactly. Instead, regulators approve biosimilars - medicines that are highly similar to an already authorised biologic and have no clinically meaningful differences in safety, quality, or effectiveness. These medicines undergo rigorous evaluation before approval and are continuously monitored once they are in use.
Understanding this in theory is one thing. Experiencing it as a patient is another.
When I was first prescribed Remsima, the biosimilar of Infliximab, I was cautious but hopeful. Like many people living with Crohn's Disease, I had concerns. When you finally find a treatment that brings stability, the idea of relying on something described as "similar" can be unsettling. That hesitation is not rooted in science, but in fear - fear of losing control, fear of going backwards.
For a time, Remsima worked. It helped stabilise my condition and allowed me to get on with life. That experience mattered, because it confirmed something important: biosimilars work. They are not inferior medicines and they are not shortcuts. They are effective, well-regulated treatments that deliver real benefits to patients.
But Crohn's Disease has a way of reminding you that nothing is guaranteed. Eventually, Remsima stopped working for me. That was not a failure of biosimilars; it was the nature of the disease. Loss of response happens with biologic treatments, whether they are original products or biosimilars. Many patients face this reality, and it highlights why access to multiple treatment options is so critical.
My treatment was then switched to Uzpruvo, the biosimilar of Stelara (ustekinumab). Once again, change brought anxiety. Anyone living with a chronic illness understands that feeling: the fear that the next treatment might not work, that side effects could emerge, or that fragile stability could be lost. These concerns are not theoretical - they are deeply personal.
The transition was handled carefully, with appropriate medical oversight and monitoring. Our health system and our professionals are second to none. Uzpruvo has allowed my treatment to continue and my condition to remain under control. That continuity matters. It means planning rather than cancelling, working rather than recovering, and living rather than merely coping. For someone with Crohn's Disease, stability is not something to take for granted.
This is why generic medicines and biosimilars matter so much. They are not about lowering standards or prioritising savings over patients. They are about ensuring that effective treatment remains available, flexible, and sustainable over time. They allow healthcare systems to treat more people, reinvest in innovation, and respond when one treatment inevitably stops working and another is needed.
There is also a clear fairness issue. When medicines are more affordable, access improves. Decisions are guided by clinical need rather than financial pressure. In chronic diseases like Crohn's, early and continuous treatment can prevent complications, hospital admissions, and surgery. That is better for patients and better f
That reality shapes how you understand medicine. Treatment is not something you take for a while and then leave behind. It becomes part of your routine, part of your planning, part of how you imagine your future. For people like me, discussions about medicine - especially generic medicines and biosimilars - are not abstract policy debates or budgetary exercises. They are about whether we can live stable, productive lives over the long term.
Biologic medicines transformed the treatment of Crohn's Disease. They brought control where there had been chaos, and quality of life where there had been pain and constant uncertainty. But they also came with an unavoidable truth: these treatments are expensive, and for a condition with no cure, they may be needed indefinitely. That reality makes the conversation around sustainability, access, and responsibility unavoidable.
Generic medicines are often misunderstood. At their simplest, generics are medicines that are the same as branded drugs whose patents have expired. They contain the same active ingredient, work in the same way, and are subject to the same safety and quality standards. The main difference is cost, because the manufacturer did not have to repeat the original research process. Generics have supported healthcare systems safely and effectively for decades.
Biologics, however, are more complex. They are produced using living cells, which means they cannot be copied exactly. Instead, regulators approve biosimilars - medicines that are highly similar to an already authorised biologic and have no clinically meaningful differences in safety, quality, or effectiveness. These medicines undergo rigorous evaluation before approval and are continuously monitored once they are in use.
Understanding this in theory is one thing. Experiencing it as a patient is another.
When I was first prescribed Remsima, the biosimilar of Infliximab, I was cautious but hopeful. Like many people living with Crohn's Disease, I had concerns. When you finally find a treatment that brings stability, the idea of relying on something described as "similar" can be unsettling. That hesitation is not rooted in science, but in fear - fear of losing control, fear of going backwards.
For a time, Remsima worked. It helped stabilise my condition and allowed me to get on with life. That experience mattered, because it confirmed something important: biosimilars work. They are not inferior medicines and they are not shortcuts. They are effective, well-regulated treatments that deliver real benefits to patients.
But Crohn's Disease has a way of reminding you that nothing is guaranteed. Eventually, Remsima stopped working for me. That was not a failure of biosimilars; it was the nature of the disease. Loss of response happens with biologic treatments, whether they are original products or biosimilars. Many patients face this reality, and it highlights why access to multiple treatment options is so critical.
My treatment was then switched to Uzpruvo, the biosimilar of Stelara (ustekinumab). Once again, change brought anxiety. Anyone living with a chronic illness understands that feeling: the fear that the next treatment might not work, that side effects could emerge, or that fragile stability could be lost. These concerns are not theoretical - they are deeply personal.
The transition was handled carefully, with appropriate medical oversight and monitoring. Our health system and our professionals are second to none. Uzpruvo has allowed my treatment to continue and my condition to remain under control. That continuity matters. It means planning rather than cancelling, working rather than recovering, and living rather than merely coping. For someone with Crohn's Disease, stability is not something to take for granted.
This is why generic medicines and biosimilars matter so much. They are not about lowering standards or prioritising savings over patients. They are about ensuring that effective treatment remains available, flexible, and sustainable over time. They allow healthcare systems to treat more people, reinvest in innovation, and respond when one treatment inevitably stops working and another is needed.
There is also a clear fairness issue. When medicines are more affordable, access improves. Decisions are guided by clinical need rather than financial pressure. In chronic diseases like Crohn's, early and continuous treatment can prevent complications, hospital admissions, and surgery. That is better for patients and better f